Chapter 3 106 36. Danaher, P. et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018;6(1):1–17. 37. Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25(1):89–94. 38. Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–9. 39. Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596(7870):119–25. 40. Caushi, J.X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Vol. 596, Nature. Springer US; 2021. 126–132 p. 41. Lowery, F.J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022;884(February):eabl5447. 42. Noguchi, T. et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5(2):106–17. 43. Damotte, D. et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17(1):1–10. 44. Kim, H.J., Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-sohelpful. Cancer Immunol Res. 2014;2(2):91–8.
RkJQdWJsaXNoZXIy MTk4NDMw